Defendant
1 case as defendant.
Vizgen, Inc. is a privately held life sciences company founded in 2019 with headquarters in Cambridge, Massachusetts. The company was established by researchers from Harvard University to commercialize spatial genomics technology. While specific revenue figures are not publicly disclosed, the company has over 100 employees and has raised significant venture capital funding. In 2024, Vizgen merged with Ultivue, a company specializing in multiplex proteomic biomarker detection, to expand its multi-omics capabilities.
Vizgen develops and sells tools for spatial biology, which allow researchers to see the location of genetic and protein activity within the context of tissue samples. The company's core technology is MERFISH (Multiplexed Error-Robust Fluorescence in situ Hybridization), which it exclusively licenses from Harvard University. Its main product is the MERSCOPE® Platform, an instrument that enables researchers to perform massively multiplexed, genome-scale nucleic acid and protein imaging at subcellular resolution. The platform is used in research areas such as oncology, neuroscience, and immunology to better understand the biological systems that govern health and disease.
As an operating company, Vizgen's patent litigation posture is that of a defendant. The company has been involved in one tracked case as a defendant and has not appeared as a plaintiff. This activity is consistent with a technology company defending itself against patent infringement allegations rather than an entity that primarily asserts patents. The suit was filed in the U.S. District Court for the District of Delaware, a common venue for patent litigation.
The company's only tracked litigation is a prominent case filed in 2022 by competitor 10x Genomics and Harvard University. The lawsuit alleged that Vizgen's products infringed patents related to spatial gene-analysis technology that Harvard had licensed to 10x Genomics. Vizgen countersued, alleging antitrust violations. The parties reached a settlement in early 2025 during the fourth day of the trial, resulting in the dismissal of all claims. The specific terms of the settlement were not publicly disclosed.
This case involved infringement claims by 10x and Harvard, with Vizgen filing counterclaims for non-infringement, invalidity, and antitrust violations. The parties reached a settlement in early February 2025, resolving the global patent dispute.